Comparative Pharmacology
Head-to-head clinical analysis: HIPPURAN I 131 versus PHOSPHOTOPE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HIPPURAN I 131 versus PHOSPHOTOPE.
HIPPURAN I 131 vs PHOSPHOTOPE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HIPPURAN I 131 (iodohippurate sodium I-131) is a radiopharmaceutical that is actively transported by the renal tubules, allowing dynamic imaging of renal function. The I-131 isotope emits beta and gamma radiation, enabling scintigraphic visualization of renal perfusion and excretion.
Unknown; proposed to normalize phosphate metabolism and inhibit ectopic calcification by binding to calcium and phosphate.
1 mCi (37 MBq) intravenously for adults; dose adjusted based on clinical indication and imaging protocol.
10-20 mcg/kg intravenous bolus over 1-2 minutes, may repeat every 10-20 minutes as needed for hemodynamic support. Maximum total dose: 1 mg.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours in patients with normal renal function; prolonged in renal impairment, up to 20-40 hours in severe impairment.
Terminal elimination half-life: 4-6 hours in patients with normal renal function; prolonged to 12-24 hours in moderate renal impairment (CrCl <30 mL/min) and >24 hours in dialysis-dependent patients.
Renal: >95% excreted unchanged in urine via glomerular filtration and tubular secretion; biliary/fecal: <5%.
Renal: 70-80% as unchanged drug; fecal: 15-20% as metabolites; biliary: <5%.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical